Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but that are still worth investing in: CRISPR Therapeutics (NASDAQ: CRSP) and ...

More than three dozen chemistry laureates join broad coalition to advocate for high risk, high reward research to keep the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A group of scientists says they will bring back the woolly mammoth by late 2028, and they just announced that they raised ...

Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

From fighting diseases to determining why you can't stand cilantro, genetics are the silent architects of your life. Here's ...

Infertility is a major global challenge associated with physiological and psychological impact. Genetic mutations that affect ...